Abstract
We report that calcipotriol (CPT) is a potent inhibitor of lymphocyte proliferation in mixed epidermal cell lymphocyte reactions. In this model, CPT and cyclosporine A (CsA) have synergistic effects. These results have led to a randomised double-blind therapeutic study protocol in patients with severe psoriasis. In these patients, topical CPT and sub-therapeutic doses of CsA (2mg/kg/d) induce disappearance of cutaneous lesions. This therapeutic association may minimize secondary side effects of both drugs.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Calcitriol / administration & dosage
-
Calcitriol / analogs & derivatives*
-
Calcitriol / pharmacology
-
Calcitriol / therapeutic use
-
Cell Division / drug effects
-
Chronic Disease
-
Cyclosporine / pharmacology
-
Cyclosporine / therapeutic use*
-
Dermatologic Agents / administration & dosage
-
Dermatologic Agents / pharmacology*
-
Dermatologic Agents / therapeutic use*
-
Dose-Response Relationship, Drug
-
Double-Blind Method
-
Drug Synergism
-
Female
-
Humans
-
In Vitro Techniques
-
Lymphocyte Culture Test, Mixed
-
Lymphocytes / cytology
-
Male
-
Psoriasis / drug therapy*
Substances
-
Dermatologic Agents
-
calcipotriene
-
Cyclosporine
-
Calcitriol